Scie News
  • Sections
    • Health
    • Africa R&D
    • Biotech
    • In the Lab
    • First Opinion
  • Topics
    • Malaria/HIV/TB
    • Biotechnology
    • Cancer
    • Infectious Disease
    • Public Health
    • Agriculture
    • Environment
    • Governance
  • Multimedia
    • The Readout Loud
    • Science Happens
    • All Video
  • Newsletters
  • More
    • Most Popular
No Result
View All Result
Try Scie Plus
  • Sections
    • Health
    • Africa R&D
    • Biotech
    • In the Lab
    • First Opinion
  • Topics
    • Malaria/HIV/TB
    • Biotechnology
    • Cancer
    • Infectious Disease
    • Public Health
    • Agriculture
    • Environment
    • Governance
  • Multimedia
    • The Readout Loud
    • Science Happens
    • All Video
  • Newsletters
  • More
    • Most Popular
No Result
View All Result
Scie News
No Result
View All Result

Gates Foundation promises funding inspite of South Africa variant news

Esther Nakkazi by Esther Nakkazi
February 10, 2021
in Health
0
Africa promote appropriate agricultural technologies and innovations for agri-business resilience in COVID
0
SHARES
12
VIEWS
Share on FacebookShare on TwitterShare on LinkedinShare on WhatsappEmail a friend

By Esther Nakkazi

The Bill and Melinda Gates Foundation has expressed disappointment at the news of the COVID-19 vaccine developed by the University of Oxford and AstraZeneca which appears to provide no measurable effect on mild or moderate disease caused by the SARS-CoV-2 variant of the virus first identified in South Africa, known as B.1.351. But has promised to fund vaccinations in poor countries.

“This is deeply disappointing news. We’ve all been spoiled lately by how good the news on vaccine science has been,” said Mark Suzman, CEO Gates Foundation.

Researchers at the University of the Witwatersrand in Johannesburg, which is running a trial of the vaccine in South Africa, released early data from a study of 2,000 patients aged between 18 and 65 years showing a substantial drop in the vaccine’s neutralizing activity against the  South African variant following the administration of two doses. The vaccine demonstrated high efficacy against wild-type SARS-CoV-2.

Researchers noted that the study did not assess the vaccine’s efficacy against severe disease from the variant. So at the moment, there is no data if this vaccine could protect against severe or fatal disease caused by the variant.

Several safe and effective vaccines against COVID-19 have been developed within the space of only 10 months—the fastest humans have ever gone from identifying a novel virus to inoculating against it. With several additional vaccines coming through the final phases of clinical trials, including those from Johnson & Johnson and  Novavax, we are still on a trajectory to get everyone protected against COVID-19. It will take time for doses of those vaccines to become available, following regulatory approvals and manufacturing and scale-up.

“The World Health Organization and national health authorities will determine the potential public health
value of this vaccine in South Africa and other countries and make decisions about where and how it
can be used,” said Suzman.

However, the Foundation credits the South African researchers for generating valuable new knowledge that will enable more targeted interventions, helping governments make important decisions about vaccine rollouts and better protect their people. A version of this vaccine is being rolled out in India, where B.1.351 hasn’t yet been detected.

The philanthropy, promises to continue to do our part to keep up the momentum. Building on our
longstanding partnerships, we are working with governments, multilateral organizations, and private
companies to determine how to respond to the latest data said the Gates Foundation.

“We will use our funding commitments of more than $1.75 billion to help accelerate the development and distribution of vaccines that are optimized for lower- and middle-income countries and are effective against the variants.”

The Foundation committed to making new investments in treatments and diagnostics because we’ve learned that research and development on these important tools must accelerate as additional variants emerge.

ends.

Tags: #Covid-19#GatesFoundation#SouthAfricaWHO
Previous Post

Launch of Africa-wide digital platform to monitor attacks on journalists

Next Post

Modern track and trace system for banana breeding

Related Posts

Africa promote appropriate agricultural technologies and innovations for agri-business resilience in COVID
Health

Life Beyond the Pandemic

February 12, 2021
Africa promote appropriate agricultural technologies and innovations for agri-business resilience in COVID
Health

New Loan Guarantee Facility Unlocks $30M for Private Sector Healthcare in Africa during COVID-19

January 21, 2021
Africa promote appropriate agricultural technologies and innovations for agri-business resilience in COVID
Health

Africa’s largest clinical trial on COVID-19 treatment launches in 13 countries

November 30, 2020
How Mauritius Fought the COVID-19 Pandemic and Won
Health

How Mauritius Fought the COVID-19 Pandemic and Won

November 29, 2020
First medical training school to be opened in Sudan rebel-held territory next year
Health

First medical training school to be opened in Sudan rebel-held territory next year

November 23, 2020
New treatment approved for Malaria
Health

A rare blood group called Dante protects against malaria

September 23, 2020
Next Post
Modern track and trace system for banana breeding

Modern track and trace system for banana breeding

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Most Popular

  • Facebook partners with African NGOs for Safer Internet day 2019

    Facebook partners with African NGOs for Safer Internet day 2019

    0 shares
    Share 0 Tweet 0
  • Kampala residents interest in Chinese Acupuncture therapy piqued

    0 shares
    Share 0 Tweet 0
  • Mbarara University innovation accelerates towards commercialisation

    0 shares
    Share 0 Tweet 0
  • Baylor-Uganda Leadership training improves healthcare outcomes

    0 shares
    Share 0 Tweet 0
  • Ugandan study to facilitate long-term research on risk factors for Non-Communicable Diseases 

    0 shares
    Share 0 Tweet 0
Scie News

© 2018 Scie News - Powered by Cyberspro.

Reporting on science from Africa

  • About Us
  • Advertise
  • Contact Us

Follow Us

No Result
View All Result

© 2018 Scie News - Powered by Cyberspro.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In